10-Q: Allarity Therapeutics Reports Third Quarter 2024 Results, Cites Intangible Asset Impairment

Allarity Therapeutics reported its third quarter 2024 results, including a significant impairment charge on intangible assets and ongoing efforts to secure additional funding.

Summary

• Allarity Therapeutics, a clinical-stage pharmaceutical company, released its financial results for the third quarter of 2024, showing a net loss of $17.1 million for the nine-month period ending September 30, 2024.
• The company's operating expenses totaled $19.9 million for the nine-month period, including a $9.7 million impairment charge on intangible assets related to its stenoparib development program.
• Research and development expenses were $4.2 million for the nine-month period, a slight decrease from $4.5 million in the same period of 2023.
• General and administrative expenses decreased to $6.0 million for the nine-month period, compared to $7.8 million in the same period of 2023.
• The company's cash and cash equivalents stood at $18.5 million as of September 30, 2024.
• Allarity has an accumulated deficit of $111.5 million as of September 30, 2024.
• The company has been actively raising capital through an at-the-market (ATM) offering, generating $33.1 million in net proceeds during the nine-month period.
• The company also issued and redeemed convertible preferred stock during the quarter, resulting in a net decrease in cash of $0.6 million.
• Allarity has been involved in a number of transactions including reverse stock splits, and amendments to agreements with 3i and Eisai.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with significant losses, an impairment charge, and ongoing legal and regulatory issues. While the company has raised capital, the overall tone is negative due to the substantial risks and uncertainties.

Positives

• The company successfully raised $33.1 million through an at-the-market (ATM) offering, bolstering its cash position.
• General and administrative expenses decreased by $1.8 million for the nine-month period compared to the same period in 2023.
• The company has taken steps to maintain its Nasdaq listing by implementing reverse stock splits.
• The company has no outstanding debt to Eisai after paying $850,000 on August 20, 2024.

Negatives

• The company incurred a significant $9.7 million impairment charge on intangible assets, reflecting challenges in its stenoparib program.
• Allarity reported a substantial net loss of $17.1 million for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $111.5 million.
• The company received a Wells Notice from the SEC, indicating potential enforcement action related to past disclosures.
• A class action lawsuit has been filed against the company and certain officers, alleging securities law violations.
• The company has halted enrollment in the ongoing Phase 2 trial of stenoparib.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company is subject to risks common to the biotechnology industry, including clinical trial failures and regulatory hurdles.
• The SEC investigation and class action lawsuit could result in significant financial and reputational damage.
• The company's reliance on third-party manufacturers for its research and development programs poses a risk.
• The company's ability to successfully develop and commercialize its drug candidates is uncertain.
• The company's financial performance is subject to unstable global market and economic conditions.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses over at least the next several years as it advances its drug candidate through clinical trials, pursues regulatory approval, and operates as a public company. The company plans to seek additional funding through public equity, private equity, debt financing, collaboration partnerships, or other sources.

Management Comments

• Management believes that the company's existing cash and cash equivalents will be sufficient to fund its anticipated expenditures and commitments for the next twelve months.
• Management maintains that the company's actions were appropriate in regards to the SEC Wells Notice and is pursuing the Wells Notice process.
• Management believes that the class action lawsuit is without merit and plans to vigorously defend itself against these claims.

Industry Context

The biotechnology industry is characterized by high risk and high reward, with companies often facing significant challenges in drug development and regulatory approval. Allarity's situation reflects these industry-wide challenges, including the need for substantial capital, the risk of clinical trial failures, and the potential for regulatory setbacks. The company's focus on personalized medicine and its DRP platform aligns with broader trends in the industry towards more targeted and effective therapies.

Comparison to Industry Standards

• The $9.7 million impairment charge on intangible assets is a significant event, and while not uncommon in the biotech industry, it highlights the risks associated with drug development. Companies like Veru Inc. have also experienced significant asset impairments in the past, demonstrating the volatility of the sector.
• The company's cash burn rate and reliance on ATM offerings for funding are typical for clinical-stage biotech companies. Companies like Cassava Sciences have also utilized ATM offerings to raise capital, but this can lead to dilution for existing shareholders.
• The SEC investigation and class action lawsuit are serious issues that can significantly impact a company's valuation and future prospects. Other companies like TG Therapeutics have faced similar regulatory and legal challenges, which can lead to significant market volatility.
• The reverse stock splits implemented by Allarity are a common strategy for companies facing delisting from major exchanges. Companies like Ocugen have also implemented reverse stock splits to maintain compliance with listing requirements.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a Wells Notice from the SEC relating to disclosures regarding meetings with the FDA about the Dovitinib NDA.
• A class action lawsuit was filed against the company and certain officers alleging false and misleading statements related to the Dovitinib NDA.

Related Party Transactions

• Thomas H. Jensen, a director of the Company, was paid $0.2 million in fees as a consultant during the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial losses, legal challenges, and potential dilution from future capital raises.
• Employees may experience uncertainty due to the company's financial instability and potential restructuring.
• Customers and partners may be concerned about the company's ability to continue its operations and development programs.
• Creditors may face increased risk due to the company's financial challenges and potential for default.

Next Steps

• The company plans to continue its clinical development efforts for stenoparib.
• The company will continue to cooperate with the SEC investigation and defend itself against the class action lawsuit.
• The company will seek additional funding through various sources to support its operations.
• The company will continue to monitor and comply with Nasdaq listing requirements.

Key Dates

Keywords

Allarity Therapeutics, biopharmaceutical, clinical stage, cancer, stenoparib, DRP, Drug Response Predictor, reverse stock split, ATM offering, SEC investigation, class action lawsuit, intangible asset impairment, convertible preferred stock, Nasdaq, 3i, Eisai